Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Adalimumab in Non-infectious Uveitis
NCT01148225Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2010
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Intermediate Uveitis (IU), Posterior Uveitis and panuveitis, sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events at 366 weeks, Number of Participants With Potentially Clinically Significant (PCS) Hematology Values at 366 weeks and 2 more. Started Nov 2010; status: completed.
02
Drugs
03
Conditions
Intermediate Uveitis (IU)Posterior Uveitispanuveitis
Beyond the preview
Go deeper on NCT01148225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148225.